Molecular analysis of the arylsulphatase A gene in late infantile metachromatic leucodystrophy patients and healthy subjects from Italy

Stefano Regis, Mirella Filocamo, Marina Stroppiano, Fabio Corsolini, Rosanna Gatti

Abstract
A molecular analysis of the arylsulphatase A gene was performed on 26 unrelated, Italian, late infantile metachromatic leucodystrophy patients. The frequency of the common disease causing mutations 609A and 2381T was 28-8% and 1-9% respectively. Pseudodeficiency allele frequency in patients was found to be 13-5% and a frequency of 10-1% was found in 89 unaffected normal controls. The frequency of the 609A mutation in Italian late infantile patients is lower than in late infantile patients from northern Europe, suggesting a higher frequency of different sporadic mutations in the Italian population. A cooperative in cis effect in phenotype determination involving arylsulphatase A mutations and the eventual background of the pseudodeficiency allele is proposed.

Key words: arylsulphatase A gene; late infantile metachromatic leucodystrophy.

Metachromatic leucodystrophy (MLD) is an autosomal recessively inherited disorder resulting from the deficiency of the lysosomal hydrolase arylsulphatase A (ASA). Three different clinical forms of MLD can be distinguished according to the age of onset: a late infantile, a juvenile, and an adult form.

We report the results of screening performed on 26 unrelated, Italian, late infantile MLD patients from different parts of Italy. Patients were investigated for the two most frequent ASA mutations causing MLD: 609A, common in the late infantile phenotype, and 2381T, common in the adult phenotype (fig 1).23 In addition, patients were screened for the pseudodeficiency associated ASA mutations (1788G and 2723G) that cause a non-pathological 90% reduction of ASA activity in homozygous carriers (fig 2). Pseudodeficiency (pd) allele screening was performed on our patients and on 89 normal controls. Patients were diagnosed by enzymatic assay on cultured fibroblasts. The clinical form of MLD was determined by the age of onset of symptoms.

The frequency of the 609A mutation was 28-8% (15 alleles out of 52, fig 3), which is lower than the frequency found in other groups of late infantile MLD patients, such as 44-8% among late infantile MLD patients diagnosed in Germany (26 alleles out of 58),6 and 55-5% among late infantile MLD patients diagnosed in Britain (10 alleles out of 18).7 This suggests that in Italy there is a higher frequency of rare mutations causing the late infantile phenotype than in northern European populations.

The frequency of mutation 2381T among our patients was 1-9% (one allele out of 52, fig 3). This low frequency is not surprising, because the 2381T mutation is typical of milder phenotypes. The only patient heterozygous for the 2381T mutation is a rare case of a late infantile carrier of this mutation. He was also not a carrier of the 609A mutation.

Patients and normal controls were also screened for the pd allele (fig 3). Among the patients, the frequency of the pd allele was 13-5% (seven alleles out of 52), while among 89 unrelated normal controls the frequency was 10.1% (18 alleles out of 178).

Among the patients who carry the 609A mutation, only one 609A heterozygous is also heterozygous for the pd allele. The only patient carrier of the 2381T mutation is also heterozygous for the pd allele. Normal and pd related PCR products obtained with specific oligonucleotides8 from this last patient were used for subsequent screening for mutation 2381T. Results obtained showed that mutation 2381T and pd associated mutations lie on the same allele in the patient described (data not shown).

Figure 1 Screening for mutations 609A and 2381T by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.1 It consists of PCR amplification of two fragments of 160 bp and 100 bp containing the sites of mutations 609A and 2381T respectively. In the presence of mutation 609A the 160 bp is XbaI digested into two fragments of 130 bp and 30 bp. In the presence of mutation 2381T the 100 bp product is PstI digested into two fragments of 70 bp and 30 bp. Lane M: ΦX174 DNA HaeIII digested; lanes 1-6: PCR products from six patients; lanes 1A-6A: XbaI and PstI digested PCR products from the same patients. Patients 1 and 5 are homozygous for the 609A mutation; patient 4 is heterozygous for the 2381T mutation.
26 MLD patients

<table>
<thead>
<tr>
<th>Allele Combination</th>
<th>Patients with pd allele</th>
<th>89 controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>2381T/2381T</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>2381T/-</td>
<td>3</td>
<td>16</td>
</tr>
<tr>
<td>609A/609A</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>609A/-</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>pd/pd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pd/n</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>f (2381T) = 1.9%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>f (609A) = 28-8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>f (pd) = 13.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>f (pd) = 10-1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. Screening for the pd allele according to a differential amplification method. It consists of separate amplifications of the normal and the pd allele with specific oligonucleotides. In both cases, PCR products are 995 bp long; each normal or pd allele specific amplification is coupled to the amplification of a pd independent control fragment of 774 bp. Lane M: 5X174 DNA HaeIII digested; lanes 1–7: amplification with normal allele specific oligonucleotides performed on seven patients; lanes 1A–7A: amplifications with pd allele specific oligonucleotides performed on the same seven patients. Patient 5 is homozygous for the pd allele; patients 2 and 7 are heterozygous for the pd allele; no pd alleles are present in patients 1, 3, 4, 6.

Figure 3. Results of screening for mutations 609A, 2381T, and pd associated ASA mutations performed on 26 unrelated, Italian, late infantile MLD patients and for pd mutations performed on 89 unrelated, Italian, normal controls. Patients and normal controls homozygous and heterozygous for the screened mutations and allelic frequencies are indicated. n is an unknown MLD causing ASA mutation. m is a non-pd allele.

Pd allele frequencies found among patients and healthy controls (13-5% and 10-1% respectively) are in the range found in other populations (7-3% to 15%), but the higher frequency found among patients suggests that it could be possible that certain mutations have more severe consequences if located on a pd allele than if located on a non-pd allele. With a similar cooperative in cis effect, the late infantile phenotype of the above mentioned patient carrier of the 2381T mutation on a pd allele could be explained. At present, however, we cannot exclude that an additional mutation is present in this allele and is effectively responsible for the observed phenotype. The high frequency of the pseudodeficiency in the general population and the existence of MLD causing mutations on pd alleles illustrate the problems associated with diagnosis of MLD, which needs a multiple approach, biochemical and molecular, to differentiate between MLD and pd associated ASA deficiencies.

This work was supported by Italian Telethon grants A.25 and C.02/1993.

Molecular analysis of the arylsulphatase A gene in late infantile metachromatic leucodystrophy patients and healthy subjects from Italy.

S Regis, M Filocamo, M Stroppiano, F Corsolini and R Gatti

doi: 10.1136/jmg.33.3.251

Updated information and services can be found at:
http://jmg.bmj.com/content/33/3/251

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/